盘中涨停！这家公司控制权拟变更，明起停牌

Core Viewpoint - Tai Long Pharmaceutical (600222) is undergoing a potential change in control due to the share transfer plan by its controlling shareholder, Zhengzhou Tai Rong Industrial Investment Co., Ltd. [1] Group 1: Share Transfer and Control Change - Zhengzhou Tai Rong Industrial Investment Co., Ltd. is planning to transfer shares, which may lead to a change in the company's control [1] - The stock of Tai Long Pharmaceutical was suspended from trading starting December 2, with an expected suspension period of no more than two trading days [1] - As of September 30, 2025, Tai Rong holds 82.44 million shares, accounting for approximately 14.37% of the company, making it the largest shareholder [1] Group 2: Financial Performance - For the first three quarters of 2025, Tai Long Pharmaceutical reported revenue of 1.187 billion yuan, a year-on-year decrease of 11.47%, and a net profit attributable to shareholders of 25.33 million yuan, down 12.36% year-on-year [2] - The decline in revenue is attributed to the company's main products participating in the national collection of traditional Chinese medicine, which has not yet fully covered the bidding work [2] Group 3: Business Operations and Strategy - Tai Long Pharmaceutical's main business includes drug manufacturing and research services, focusing on traditional Chinese medicine, drug formulations, and drug circulation [2] - The company aims to enhance its capabilities in funding, resources, and industrial integration through Tai Rong, promoting strategic development in traditional Chinese medicine, CXO, and health sectors [2] - The company is currently advancing the bidding work for selected products in the national collection of traditional Chinese medicine, with plans to manage inventory and supply chain effectively during the peak sales season for respiratory medications [3]